Menlo Park,  CA 
United States
  • Booth: 1020

PacBio® SMRT® Sequencing delivers highly accurate long reads for the most comprehensive view of human genetic variation. Our new Sequel® II System generates ~8-times more data making long-read sequencing more affordable. PacBio end-to-end sequencing solutions include whole genome sequencing for variant detection, structural variant discovery, and de novo assembly, full-length RNA sequencing, and targeted sequencing including our No-Amp approach.

 Press Releases

  • MENLO PARK, Calif., October 10, 2019 — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that more than 50 presentations will include data from the company’s Single Molecule, Real-Time (SMRT®) sequencing platforms at next week’s American Society for Human Genetics (ASHG) 2019 annual meeting in Houston. These presentations include conference talks, posters, an educational workshop, and exhibit hall demonstrations.

    PacBio will host a workshop titled “Accurate and Affordable Long-Read Sequencing of Human Genomes on the Sequel® II System,” which will take place on Wednesday, October 16, 2019 from 12:45 p.m. to 2:00 p.m. in Lanier Ballroom AB at the Hilton Americas-Houston hotel. The program will be hosted by Chief Scientific Officer Jonas Korlach, PhD, and will update attendees on the latest Sequel II software and chemistry release for highly accurate long-read sequencing. Speakers at the workshop include:

    • Shawn Levy, PhD, Faculty Investigator, Genomic Services Laboratory, HudsonAlpha Institute for Biotechnology, who will share information about the Insitute's adoption of PacBio human whole-genome sequencing for multiple on-going human genetics projects – including the NIH-funded Clinical Sequencing Exploratory Research (CSER) project.
    • Naomichi Matsumoto, MD, PhD, Chair of Human Genetics at Yokohama City University, who will discuss the use of PacBio long-read sequencing for disease genome analysis.
    • Emily Hatas, Senior Director of Business Development at PacBio, who will present information about the latest advancements in SMRT Sequencing for human genetics research, including the new Sequel II Consumables 2.0 and SMRT Link v8.0 release, and ways users can now detect structural variants for up to two ~3Gb genomes, or characterize alternative splicing acrossa whole transcriptome, with just one SMRT Cell 8M.

    Interested attendees can pre-register for the workshop.

    “We are looking forward to sharing our latest product updates and scientific advances with the human genetics community, which will allow them to sequence human genomes and transcriptomes with confidence,” said Dr. Korlach. “Through our workshop and other presentations, attendees will be able to see the power of SMRT Sequencing for de novo genome assembly, targeted sequencing, isoform sequencing and variant detection, including finding important structural variants.”

    The following podium and poster presentations represent a selection of the more than 50 presentations that will include SMRT Sequencing data, which represents a doubling over the number last year.

    Platform Presentations:

    • #57 on Wednesday, 10/16 at 5:30 p.m.: “Single-cell isoform RNA sequencing characterizes isoforms in thousands of cerebellar cells,” by Hagen Tilgner, PhD, from Weill Cornell Medicine.
    • #221 on Thursday, 10/17 at 4:15 p.m.: “A robust and production-level approach to haplotype-resolved assembly of single individuals,” moderated by Avery Davis Bell from Harvard Medical School and Joanna Kaplanis, from the Wellcome Sanger Inst, Hinxton, UK.
    •  #223 on Thursday, 10/17 at 4:15 p.m.: “Long-read single molecule, real-time (SMRT) sequencing of NUDT15: Phased full gene haplotyping and pharmacogenomic allele discovery,” with Yao Yang, PhD, from the Icahn School of Medicine at Mount Sinai.
    •  #313 on Saturday, 10/19 at 9 a.m.: “Incorporating long transcriptomic data into GENCODE,” with Jane Loveland, PhD, from European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, United Kingdom.

    Poster Presentations:

    • Poster #1068: “Comprehensive structural and copy-number variant detection with long reads,” by Aaron Wenger, PhD, of PacBio.
    • Poster #1455: “Full-length RNA-seq of Alzheimer brain sample on the PacBio Sequel II platform,” by Elizabeth Tseng, PhD, of PacBio.
    • Poster #1692: “High-quality human genomes achieved through HiFi sequence data and FALCON-Unzip Assembly,” by Zev Kronenberg, PhD, of PacBio.
    • Poster #1866: “Detection and phasing of small variants in Genome in a Bottle samples with highly accurate long reads,” by William Rowell of PacBio.

    Other scientific program highlights featuring SMRT Sequencing include the CoLab Session on Friday, October 18 at 10:00 a.m. in Theater 3, where ASHG meeting attendees will have the opportunity to hear from PacBio scientists on the exhibit hall floor in the session “PacBio Sequel II System: Structural Variants and Whole Transcriptome in 1 SMRT Cell Each.” The session will include talks on whole genome sequencing for structural variation discovery and Iso-Seq® Analysis. Attendees can also visit PacBio at booth #1020.

    PacBio will be sponsoring a grant program for scientists interested in a chance to win free SMRT Sequencing for their human genetics sequencing projects, including scientists who are not attending this year’s ASHG annual meeting. For more information visit

    About Pacific Biosciences

    Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at

    Forward-Looking Statements

    All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to product updates or enhancements, upcoming conference presentations, the attributes of the Sequel II System, the future availability, uses, accuracy, quality or performance of, or benefits of using, products or technologies, the suitability or utility of methods, products or technologies for particular applications, studies or projects, the importance of long-read sequencing data, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.



    Nicole Litchfield



    Trevin Rard



    Discovery Contact:                             PacBio Contact:

    Jodie Klein 703/801-7955                   Nicole Litchfield 415/793-6468    


    Significant Investment to Accelerate Cancer Research Creates First Commercial Single Source for Combined FFPE Acquisition, FFPE RNA Isolation and Long-Read Sequencing

    HUNTSVILLE, Ala., October 15, 2019— Discovery Life Sciences™(Discovery) announced today its substantial investment in long-read genomic sequencing technology from Pacific Biosciences (PacBio). The instrumentation will complement the existing infrastructure of HudsonAlpha Discovery™, Discovery’s genomic sequencing and bioinformatics division.  HudsonAlpha Discovery will continue to scale sequencing over a range of technologies, creating the most comprehensive infrastructure to support the most accurate and complete analysis of complex genomic and transcriptomic projects possible. This investment creates a PacBio® Center of Excellence for long-read sequencing.

    Existing short-read sequencing is like a complex jigsaw puzzle. Researchers align and merge many short DNA sequences to reconstruct a representation of the reference genome, but the alignment and assembly from short reads has limitations. Long-read sequencing provides additional power and context; recent studies show that it detects structural variants in disease genes that are missed by previous methods. Combining short- and long-read sequencing creates a depth and breadth to comprehensively understand the complex genomics driving cancer and other diseases.

    The multiple PacBio Sequelâ II Systems that Discovery is acquiring provide highly accurate long reads and supplement HudsonAlpha Discovery’s existing short-read platforms to add resolution across both DNA and RNA applications. In addition to whole genome sequencing for variant detection, the Sequel II Systems will provide high-volume capacity for long-read RNA sequencing of gene isoforms. These sequencing services, combined with the HudsonAlpha Discovery proprietary methods for long-fragment RNA isolation from FFPE and access to millions of FFPE biospecimens, deliver a novel set of applications to the entire genomics community.

    Most cancer biospecimens are stored in a Formalin-Fixed, Paraffin-Embedded (FFPE) format, and Discovery has the largest global inventory—millions of high-quality FFPE biospecimens.  HudsonAlpha Discovery is committed to extracting the highest resolution data from those specimens and has developed a proprietary methodology to extract long transcripts from FFPE materials. The investment in the Sequel II System will be used to characterize these transcipts for gene fusions, RNA modifications, and other structural alterations that are best resolved with long-read sequencing. 

    “This investment enables HudsonAlpha Discovery to conduct long-read sequencing of thousands of high-quality human genomes per year. We’ve developed methods to significantly improve the integrity of RNA isolated from FFPE; now we are marrying the PacBio technology with our proprietary method to improve our ability to see the RNA transcripts in cancer biology,” said Shawn Levy, PhD, Discovery’s chief scientific officer, Genomics. “With these holistic solutions, Discovery is uniquely positioned to help researchers advance their understanding of complex diseases by providing a single partner from specimen selection to short- and long-read sequencing and, finally, to data interpretation and actionable result delivery.”

    "We are pleased to be working closely with Discovery Life Sciences as they set up the highest-throughput PacBio Sequencing facility in the world with a goal to advance disease research and population studies," said Jonas Korlach, PhD, chief scientific officer at Pacific Biosciences.

    “We continue to aggressively invest in our laboratory resources to support the rapid advancement of our clients’ research timelines and objectives,” said Glenn Bilawsky, Discovery’s CEO. “Our long-read sequencing services will provide the market with a single source to derive high-quality data from our PacBio systems, in combination with our other offerings in sequencing, cell-based, immunohistochemistry services.  Discovery is the first to bundle this combination of scientific services and technology platforms alongside one of the largest global biospecimen inventories under one brand.”

    About Discovery Life Sciences 

    Discovery Life Sciences is the global market leader in biospecimen analysis, procurement, distribution, and scientific services for the pharmaceutical, biotechnology, and diagnostics industries. HudsonAlpha Discovery is Discovery’s sequencing and bioinformatics division, a globally recognized service laboratory that leverages the most current genomic research technologies to comprehensively support discovery, translational, and clinical research. Driven by science, the Discovery team engages with customers in an innovative, consultative approach to overcoming obstacles and reaching a faster end result. We are Science at your Service™! For more information, visit



    Shawn Levy, PhD, will make several presentations on long-read sequencing at the American Society of Human Genetics (ASHG) Annual Meeting, October 15-19 in Houston, Texas. 

    1. Utilization of a Single Strategic Partner for Biospecimens and Genomic Services Including Significantly Improved Methods for FFPE RNA Extraction and Whole Exome Sequencing with Deep Coverage of Solid Tumor Variants

    Wednesday, October 16 12:45-1:30

    CoLab #1, Booth 345

    1. Long Read Sequencing in Oncology and Population Research: Perspectives and Opportunities

    Wednesday, October 16, 12:45-2:00 p.m. CDT
    Hilton Americas-Houston, Lanier Ballroom AB, Level 4

Questions or Need Assistance?


Technical support: Support

For more tips, visit the FAQ.

Featured Products
View All

Want your product featured here? Click to upgrade your online exhibitor listing.